Where Will Pfizer Be in 5 Years?
Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer stockpiling vaccines and it will be the commercial market that buys them, demand will be much lighter. On top of that, Pfizer is also dealing with multiple drugs losing patent protection in the near future, exacerbating concerns about its growth potential.
With so many moving parts, it can be difficult to predict how everything will play out and where Pfizer will be in the future. Below, I'll look at how the business might look five years from now, and whether that makes it a stock worth buying today.
One thing I'm not expecting to be a big revenue driver for the business is COVID-19. Even if there is an uptick in case numbers, unless it is truly devastating, demand likely won't be strong for Pfizer's COVID-19 vaccine or booster shots in the future. This year, Pfizer projects the COVID-19 vaccination rate in the U.S. to be just 24%. In the future, that rate is likely to decline even further as COVID-19 becomes even less of a concern.
Source Fool.com
Pfizer Inc. Aktie
Die Community zeigt eine Präferenz für Buy-Einschätzungen bei Pfizer Inc..
Das Kursziel von 29 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 20% gegenüber 23.14 €.
